Drug Study Ambroxol

Rez Gioz P. Apego N-40 Patient’s name: Casugudan Name of Drug Generic Name: Ambroxol Hydrochlori de Trade Name: Mucosolvan and Mucoangin Availability: Tablets—30 mg;

January 27, 2014

Classification of Drug Therapeutic: Mucolytic Pregnancy Category A

Mechanism of Action 

It enhances pulmonary surfactant production and stimulates ciliary activity. These actions result in improved mucus flow and transport (mucociliary clearance). Enhancement of fluid secretion and mucociliary clearance facilitates expectoration and eases cough.

Indication

Adjuvant therapy in patients with abnormal, viscid, or inspissated mucous secretions in acute and chronic bronchopulmonary diseases, and in pulmonary complications of cystic fibrosis and surgery, tracheostomy, and atelectasis.

Contraindications 



Should not be used in patients known to be hypersensitiv e to ambroxol or other components of the formulation. There are no absolute contraindicatio n but in patients with gastric ulceration relative caution should be observed.

Side Effects 

There are no such harmful side effects of the medicine. It is usually well tolerated. In some cases, nausea and vomiting might occur.

Nursing Responsibilities •Monitor for S&S of aspiration of excess secretions, and for bronchospasm (unpredictable);withhold drug and notify physician immediately if either occur. •Lab tests: Monitor ABGs, pulmonary functions and pulse oximetry as indicated. •Have suction apparatus immediately available. Increased volume of respiratory tract fluid may be liberated; suction or endotracheal aspiration may be necessary to establish and maintain an open airway. Patient & Family Education •Report difficulty with clearing the airway or any other respiratory distress

Chief complaint: Cough and Fever